| Issue |
Radioprotection
Volume 60, Number 3, Juillet-Septembre 2025
|
|
|---|---|---|
| Page(s) | 285 - 292 | |
| DOI | https://doi.org/10.1051/radiopro/2025004 | |
| Published online | 15 September 2025 | |
Article
Gamma-H2AX as a biomarker to assess individual radiosensitivity for radiopharmaceutical therapy in cancer patients: a systematic review
1
Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
2
Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, Research Organization for Nuclear Energy National Research and Innovation Agency, Tangerang, Indonesia
3
Department of Medical Pharmacy, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
4
Research Center for Safety, Metrology, and Nuclear Quality Technology, Research Organization for Nuclear Energy National Research and Innovation Agency, Tangerang, Indonesia
5
Department of Medical Biology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia
* Corresponding author: anitabio@yahoo.co.uk
Received:
19
July
2024
Accepted:
31
January
2025
Radiopharmaceutical therapy offers targeted and potent cancer treatment, but individual responses vary, necessitating personalized approaches for optimal outcomes. Gamma-H2AX, a phosphorylated form of histone, has become a sensitive indicator of DNA double-strand breaks caused by ionizing radiation. Gamma-H2AX assays in radiopharmaceutical therapy offer a non-invasive way to assess individual radiosensitivity, improving treatment optimization and patient classification. This systematic review examines the use of gamma-H2AX as a biomarker for determining individual radiosensitivity in cancer patients receiving radiopharmaceutical therapy. An in-depth search for supporting publications utilized three popular electronic databases: PubMed Central (PMC), ScienceDirect, and Scopus. Specific keywords determine article limits. Every existing article was examined and appraised independently using the PICO method (participants, intervention/exposure, comparison, and outcome). Eighty-one articles were identified, 49 were screened based on title and abstract, and 32 were excluded. Six articles were worthy, but only two were considered in this research. Based on these two articles, it is possible to conclude that the gamma-H2AX foci marker in peripheral blood cells of patients receiving radiopharmaceutical therapy was promising for predicting treatment response and individual radiosensitivity. However, this research must be validated with more patients for a higher prospective value in future investigations.
Key words: DNA damage response / gamma-H2AX / radiosensitivity / cancer / radiopharmaceutical therapy
© T. Kisnanto et al., Published by EDP Sciences 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.